Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy.
Seventy-two patients with advanced prostatic carcinoma without previous endocrine therapy were treated with an oral nonsteroidal antiandrogen, flutamide. Sixty-three patients (87.5%) had a favorable response, and 9 patients showed no response. Flutamide appears to be a safe antiandrogen, usually effective in the management of patients with advanced prostatic cancer who have had no prior endocrine therapy.
D000135:Acid Phosphatase / Q000097:blood; D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary; D000328:Adult; D000368:Aged; D000813:Anilides / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary; D002986:Clinical Trials as Topic; D005485:Flutamide / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006869:Hydronephrosis / Q000209:etiology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000150:complications / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000556:secondary; D014555:Urination Disorders / Q000209:etiology / Q000628:therapy
D000813:Anilides; D005485:Flutamide; D000135:Acid Phosphatase